GlaxoSmithKline (GSKN) Stock Price & Analysis
GSKN Stock Chart & Stats
- Day’s Range
- MXN 938.00 - MXN 940.00
- 52-Week Range
- MXN 792.01 - MXN 1,169.96
- Previous Close
- MXN 856.00
- Volume
- 0
- Average Volume (3M)
- 8
- Market Cap
- MXN 1.87T
- Enterprise Value
- MXN 125.13B
- Total Cash (Recent Filing)
- MXN 2.98B
- Total Debt (Recent Filing)
- MXN 23.86B
- Price to Earnings (P/E)
- 17.2
- Beta
- 0.21
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 13.88
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.38%
Bulls Say, Bears Say
Bulls Say
Specialty Medicines Growth And Pipeline Expansion
Strong specialty-medicine growth and a materially accelerated phase III programme broaden GSK’s future product base. Continued launches, approvals and late-stage development can improve the mix toward higher-growth franchises and support revenue durability over the coming years.
Improving Profitability And Operating Efficiency
Gross-profit growth ahead of sales, stable SG&A and a broadly stable operating margin indicate that product mix and efficiency gains are supporting profitability. This provides a foundation for funding increased R&D while preserving operating leverage through the pipeline transition.
Robust Cash Generation And Commercial Franchises
Strong cash generation gives GSK internal funding for research, launches and shareholder distributions. Its leading MenB position and established HIV, respiratory and vaccine franchises add commercial scale, helping convert innovation and market access into recurring cash flow.
Bears Say
Elevated Leverage And Rising Financing Costs
Debt-dependent financing reduces flexibility compared with a conservative balance sheet and makes earnings more sensitive to interest costs. The Nuvalent-related expense and projected higher future interest burden could constrain cash available for pipeline investment and capital returns.
Choppy Free-cash-flow Growth
Positive cash flow is supportive, but a sharp TTM contraction and prior declines show that cash conversion is not consistently expanding with earnings. Variability can limit confidence in funding capacity, especially while restructuring and R&D investment remain elevated.
Pressure On Vaccines And Inhaler Economics
Weak vaccine demand in some markets and pricing pressure in inhalers can dilute growth from stronger specialty franchises. Sustained competition, market softness and lower realized prices may weigh on mix, margins and the predictability of established-portfolio earnings.
GlaxoSmithKline News
GSKN FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
What is GlaxoSmithKline’s market cap?
When is GlaxoSmithKline’s upcoming earnings report date?
How were GlaxoSmithKline’s earnings last quarter?
Is GlaxoSmithKline overvalued?
Does GlaxoSmithKline pay dividends?
What is GlaxoSmithKline’s EPS estimate?
How many shares outstanding does GlaxoSmithKline have?
What happened to GlaxoSmithKline’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GlaxoSmithKline?
What is the TipRanks Smart Score and how is it calculated?
GlaxoSmithKline Stock Smart Score
Company Description
GlaxoSmithKline
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels
- Employees
- 66,841
- Website
- www.gsk.com
- Address
- 79 New Oxford Street, London, GL, WC1A 1DG, GB
GlaxoSmithKline (GSKN) Earnings & Revenues
GSKN Company Deck
GSKN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. GSK reported 5% sales growth, reaffirmed 2026 guidance, delivered strong cash generation, and highlighted substantial progress across launches, approvals, commercial growth, and the accelerated phase III pipeline. The main negatives were vaccine and inhaler market pressures, significant restructuring and financing costs, foreign exchange headwinds, ongoing uncertainty around the four-monthly APRETUDE formulation, and adoption or monitoring challenges for certain products.
View all MX:GSKN earnings summariesGSKN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |